- Home
- EFR vs VCRE Comparison
EFR vs VCRE Comparison
Compare EFR & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EFR | VCRE |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.6M | 271.7M |
| IPO Year | 2003 | 2026 |
Fundamental Metrics
Financial Performance| Metric | EFR | VCRE |
|---|---|---|
| Price | $10.25 | $9.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $29.03 |
| AVG Volume (30 Days) | ★ 105.9K | 23.7K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $101.29 |
| Revenue Next Year | N/A | $481.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.11 | $7.88 |
| 52 Week High | $11.48 | $14.01 |
Technical Indicators
Market Signals| Indicator | EFR | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 41.35 | 41.08 |
| Support Level | $10.17 | $8.79 |
| Resistance Level | $10.63 | $12.08 |
| Average True Range (ATR) | 0.13 | 0.84 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 19.35 | 28.40 |
Price Performance
Historical ComparisonAbout EFR Eaton Vance Senior Floating-Rate Fund of Beneficial Interest
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of Software, Health Care Providers & Services, Machinery, Chemicals, Professional Services, IT Services, Hotels, Restaurants & Leisure, Capital Markets, Specialty Retail, Commercial Services & Supplies, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.